ClinicalTrials.gg
Not yet recruitingNCT07502638Updated Mar 31, 2026

FXS6837 for the Treatment of IgAN Patients

A Phase 2 interventional study of FXS6837 Dose 1 and FXS6837 Dose 2 in IgAN, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study in approximately 60 patients with primary IgA nephropathy (IgAN).

Participants receiving background therapy will be randomized in a 1:1:1 ratio to receive FXS6837 capsules dose 1,dose 2, or placebo, administered orally once daily.

The study aims to evaluate the efficacy and safety of FXS6837 in patients with primary IgAN and to identify the optimal clinical dose.

02

Conditions studied

  • IgAN
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or female patients aged ≥18 years with -confirmed primary IgA nephropathy (IgAN), meeting all of the following:

    1. A qualifying renal biopsy performed within the past 8 years;
    2. ≤50% tubulointerstitial fibrosis;
    3. Crescent formation present in ≤50% of glomeruli;
    4. If a historical biopsy is not available, a biopsy may be performed during screening.
  2. Estimated (eGFR) ≥30 mL/min/1.73 m² at screening and at the end of the run-in period.
  3. Urine protein-to-creatinine ratio (UPCR) ≥0.75 g/g at screening and at the end of the run-in period.
  4. Vaccination against Neisseria meningitidis and Streptococcus pneumoniae is required prior to initiation of study treatment. If not previously vaccinated or if a booster is required, 5. vaccination should be administered according to local regulations at least 2 weeks prior to first dose. If treatment must begin earlier, prophylactic antibiotic therapy should be initiated.
  5. Patients must have received a stable dose of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), at the locally approved maximum daily dose or maximally tolerated dose (per investigator judgment), for at least 90 days prior to first dose. If receiving sodium-glucose cotransporter-2 inhibitors (SGLT2i), endothelin receptor antagonists (ERA), or hydroxychloroquine, doses must also be stable for at least 90 days prior to first dose (per investigator judgment).

Exclusion criteria

Exclusion criteria:

  1. Secondary IgA nephropathy (IgAN), as defined by the investigator.
  2. Rapidly progressive IgAN, defined as ≥50% decline in (CKD-EPI) within 3 months, or \<50% decline but considered by the investigator to be at risk of rapid renal function deterioration.
  3. Other systemic diseases associated with proteinuria or chronic kidney disease (e.g., diabetic nephropathy, lupus nephritis, ANCA-associated vasculitis), or severe urinary tract obstruction or dysuria.
  4. Prior treatment with agents, including but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF), mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic within 90 days (or 5 half-lives, whichever is longer) prior to first dose.
  5. Prior treatment with oral budesonide (Nefecon®) within 6 months prior to first dose.
  6. Prior treatment with other complement inhibitors within 30 days (or 5 half-lives, whichever is longer) prior to first dose.
  7. Positive test results for ; active syphilis infection; chronic infection (HBsAg positive with HBV DNA > lower limit of quantification [LOQ]); or infection (positive HCV antibody with detectable HCV RNA).
  8. Active tuberculosis at screening.
  9. abnormal liver function at screening, defined as any of the following: , AST, GGT, or ALP >3 × (ULN), or total >2 × ULN.
  10. History of meningococcal infection.
  11. Active systemic bacterial, viral (including COVID-19), or fungal infection within 14 days prior to first dose, or body temperature >38°C within 7 days prior to first dose.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm1:FXS6837 Dose 1

    Once daily

    Drug: FXS6837 Dose 1

  • Experimental
    Arm2:FXS6837 Dose 2

    Once daily

    Drug: FXS6837 Dose 2

  • Placebo comparator
    Arm3:Placebo

    Once daily

    Drug: Placebo Capsule

Interventions

  • FXS6837 taken orally once a day

    Also known as: Dose 1

  • FXS6837 taken orally once a day

    Also known as: Dose 2

  • DrugPlacebo Capsule

    Placebo taken orally once a day

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Ratio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection) at Day180

    Time frame: baseline and Day180

Secondary outcomes

  1. Ratio to baseline in Urine Protein to Creatinine Ratio at Day90

    Time frame: baseline and Day90

  2. Ratio to baseline in Urine Protein to Creatinine Ratio

    Time frame: up to Day180

  3. Ratio to baseline in Urine Albumin to Creatinine Ratio

    Time frame: up to Day180

  4. Ratio to baseline in Urinary protein excretion(UPE)

    Time frame: up to Day180

  5. Ratio to baseline in Urinary Albumin excretion(UAE)

    Time frame: up to Day180

  6. Change from baseline of serum creatinine

    Time frame: up to Day180

  7. Change from baseline of estimated glomerular filtration rate(eGFR)

    Time frame: up to Day180

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Sep 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2026
First posted
Mar 31, 2026
StartEst.
Mar 31, 2026
Primary completionEst.
Sep 12, 2027
CompletionEst.
Nov 14, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07502638
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Mar 31, 2026 (estimated)
Primary completion
Sep 12, 2027 (estimated)
Completion
Nov 14, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Jicheng LV, Doctor
Contact
jichenglv@bjmu.edu.cn
+86-10-83572211
Yang Li, Doctor
Contact
liyang_3337@163.com
+86-10-83572211
Jicheng Lv, Doctor
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FXS6837

Start the discussion